COmbination Therapy With Baloxavir and Oseltamivir 1 for Hospitalized Patients With Influenza (The COMBO Trial 1)
Status:
Recruiting
Trial end date:
2022-12-01
Target enrollment:
Participant gender:
Summary
This is a randomized, double-blind, placebo-controlled Phase 2-like, investigator-directed
trial of hospitalized patients with laboratory confirmed influenza. Eligible and consented
patients will be randomly assigned, in a 1:1 ratio, to one of two groups: Group 1, the
combination treatment group (oseltamivir and baloxavir); Group 2, the standard treatment
group (oseltamivir and placebo).